ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Avastin in Juxtafoveal Telangiectasias

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00406380
Recruitment Status : Unknown
Verified November 2006 by Asociación para Evitar la Ceguera en México.
Recruitment status was:  Recruiting
First Posted : December 4, 2006
Last Update Posted : December 4, 2006
Sponsor:
Information provided by:
Asociación para Evitar la Ceguera en México

Brief Summary:
Evaluation of efficacy of Intravitreal Injection of Bevacizumab in patients with Yuxtafoveal Telangiectasias

Condition or disease Intervention/treatment Phase
Telangiectasis Drug: Bevacizumab Procedure: Intravitreal injection of Bevacizumab Phase 3

Detailed Description:
After diagnose Yuxtafoveal telangiectasias secondary to Branch Retinal Vein Occlusion and with Idiopathic Ethiology by clinical signs and Fluorescein angiogram (FA)findings we treated patients with Intravitreal Injection of Bevacizumab (2.5mg/0.1ml). We performed a complete ophthalmological evaluation and at baseline and follow-up (1 and 3 months) we evaluate ETDRS Best Corrected visual acuity (BCVA), fluorescein angiogram (FA) and Optical Coherence Tomography (OCT)findings. We found an improvement in visual acuity and reduction of FA leakage and decrease retinal thickness in OCT.

Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Does Avastin Change Evolution in Juxtafoveal Telangiectasias?
Study Start Date : September 2006
Study Completion Date : November 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab




Primary Outcome Measures :
  1. Best corrected Visual Acuity
  2. Fluorescein Angiogram: Leakage
  3. Optical Coherence Tomography: Retinal thickness


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Patients with Telangiectasias secondary to Branch Retinal Vein Occlusion
  • Patients with Idiopathic Juxtafoveal Retinal Telangiectasias

Exclusion Criteria:

  • Diabetic Retinopathy and Diabetic Macular Edema
  • Hypertensive Retinopathy
  • Choroidal Neovascularization

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00406380


Contacts
Contact: Verónica Kon-Jara, MD 5510841400 ext 1171-1172 veronicakon@yahoo.com
Contact: Orlando Ustariz-Gonzalez, MD 5510841400 ext 1171-1172

Locations
Mexico
Asociacion para Evitar la Ceguera en Mexico Recruiting
Mexico, DF, Mexico, 04030
Contact: Veronica Kon-Jara, MD    5510841400 ext 1171-1172    veronicakon@yahoo.com   
Sub-Investigator: Orlando Ustariz-Gonzalez, MD         
Sub-Investigator: Elizabeth Reyna-Castelan, MD         
Sub-Investigator: Nelida Salazar-Teran, MD         
Sub-Investigator: Jans Fromow-Guerra, MD         
Sub-Investigator: Hugo Quiroz-Mercado, MD         
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Investigators
Principal Investigator: Veronica Kon-Jara, MD Asociación para Evitar la Ceguera en México

ClinicalTrials.gov Identifier: NCT00406380     History of Changes
Other Study ID Numbers: APEC-0024
First Posted: December 4, 2006    Key Record Dates
Last Update Posted: December 4, 2006
Last Verified: November 2006

Keywords provided by Asociación para Evitar la Ceguera en México:
Telangiectasias
Leakage
Bevacizumab
Telangiectasias secondary to Branch Retinal Vein Occlusion (BRVO)
Idiopathic juxtafoveal retinal telangiectasias

Additional relevant MeSH terms:
Telangiectasis
Vascular Diseases
Cardiovascular Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents